New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
7.5 million 'Baby shark' bath toys recalled due to serious injuries to kids

7.5 million 'Baby shark' bath toys recalled due to serious injuries to kids

by Steven ReinbergNearly 8 million Baby Shark and Mini Baby Shark bath toys have been recalled because they can cause serious injuries to children.When using these bathtoys, particularly in a ba
Pediatrics March 19,2024
7.5 million 'Baby shark' bath toys recalled due to serious injuries to kids

7.5 million 'Baby shark' bath toys recalled due to serious injuries to kids

by Steven ReinbergNearly 8 million Baby Shark and Mini Baby Shark bath toys have been recalled because they can cause serious injuries to children.When using these bathtoys, particularly in a ba
Pediatrics March 19,2024
Adverse reactions to BNT162b2 mild, moderate for 5- to 11-year-olds

Adverse reactions to BNT162b2 mild, moderate for 5- to 11-year-olds

Among children aged 5 to 11 years, most reported adverse events to BNT162b2 COVID-19 vaccination are mild-to-moderate, with few reports of myocarditis, according to a study recently published in
Pediatrics March 19,2024
Adverse reactions to BNT162b2 mild, moderate for 5- to 11-year-olds

Adverse reactions to BNT162b2 mild, moderate for 5- to 11-year-olds

Among children aged 5 to 11 years, most reported adverse events to BNT162b2 COVID-19 vaccination are mild-to-moderate, with few reports of myocarditis, according to a study recently published in
Pediatrics March 19,2024
Reported drug use among adolescents continued to hold below pre-pandemic levels in 2023

Reported drug use among adolescents continued to hold below pre-pandemic levels in 2023

by National Institutes of HealthCredit: Unsplash/CC0 Public DomainThe percentage of adolescents reporting they used any illicit substances in 2023 continued to hold steady below the pre-pandemic
Pediatrics March 19,2024
Reported drug use among adolescents continued to hold below pre-pandemic levels in 2023

Reported drug use among adolescents continued to hold below pre-pandemic levels in 2023

by National Institutes of HealthCredit: Unsplash/CC0 Public DomainThe percentage of adolescents reporting they used any illicit substances in 2023 continued to hold steady below the pre-pandemic
Pediatrics March 19,2024
Effectiveness of COVID vaccines against death remains high in children regardless of variant

Effectiveness of COVID vaccines against death remains high in children regardless of variant

by British Medical JournalCredit: Unsplash/CC0 Public DomainThe effectiveness of COVID-19 vaccines in preventing death remains high in children and adolescents regardless of the predominant circu
Pediatrics March 19,2024
Effectiveness of COVID vaccines against death remains high in children regardless of variant

Effectiveness of COVID vaccines against death remains high in children regardless of variant

by British Medical JournalCredit: Unsplash/CC0 Public DomainThe effectiveness of COVID-19 vaccines in preventing death remains high in children and adolescents regardless of the predominant circu
Pediatrics March 19,2024
COVID-19's devastating toll: A rise in adolescent mental health crises and suicidality

COVID-19's devastating toll: A rise in adolescent mental health crises and suicidality

by Children's Hospital BostonCredit: Unsplash/CC0 Public DomainThe past decade has seen a worrisome increase in mental health crises among adolescents. A new study led by Patricia Ibeziako, M
Pediatrics March 19,2024
COVID-19's devastating toll: A rise in adolescent mental health crises and suicidality

COVID-19's devastating toll: A rise in adolescent mental health crises and suicidality

by Children's Hospital BostonCredit: Unsplash/CC0 Public DomainThe past decade has seen a worrisome increase in mental health crises among adolescents. A new study led by Patricia Ibeziako, M
Pediatrics March 19,2024
1990 to 2019 saw decrease in global burden of childhood cancer

1990 to 2019 saw decrease in global burden of childhood cancer

The global burden of childhood cancer has been decreasing since 1990, according to a study published online June 11 in theJournal of Advanced Research.Ying Wu, from the College of Medicine at Zh
Pediatrics March 19,2024
1990 to 2019 saw decrease in global burden of childhood cancer

1990 to 2019 saw decrease in global burden of childhood cancer

The global burden of childhood cancer has been decreasing since 1990, according to a study published online June 11 in theJournal of Advanced Research.Ying Wu, from the College of Medicine at Zh
Pediatrics March 19,2024
Prevalence of autism up to 3.14 percent in U.S. youth for 2019 to 2020

Prevalence of autism up to 3.14 percent in U.S. youth for 2019 to 2020

The prevalence of autism spectrum disorder (ASD) in U.S. children and adolescents has increased to an estimated 3.14 percent in 2019 and 2020, according to a research letter published online July 5 in
Pediatrics March 19,2024
Prevalence of autism up to 3.14 percent in U.S. youth for 2019 to 2020

Prevalence of autism up to 3.14 percent in U.S. youth for 2019 to 2020

The prevalence of autism spectrum disorder (ASD) in U.S. children and adolescents has increased to an estimated 3.14 percent in 2019 and 2020, according to a research letter published online July 5 in
Pediatrics March 19,2024
Overall symptoms after BNT162b2, other vaccines comparable in children under five

Overall symptoms after BNT162b2, other vaccines comparable in children under five

Among children younger than 5 years, guardian-reported symptoms after BNT162b2 administration were generally comparable to those for on-label non-severe acute respiratory syndrome coronavirus 2 (SARS-
Pediatrics March 19,2024
Overall symptoms after BNT162b2, other vaccines comparable in children under five

Overall symptoms after BNT162b2, other vaccines comparable in children under five

Among children younger than 5 years, guardian-reported symptoms after BNT162b2 administration were generally comparable to those for on-label non-severe acute respiratory syndrome coronavirus 2 (SARS-
Pediatrics March 19,2024
BabySeq 2.0: Bringing equity to genomic sequencing in newborns

BabySeq 2.0: Bringing equity to genomic sequencing in newborns

by Nancy Fliesler,Children's Hospital BostonCredit: Unsplash/CC0 Public DomainToday, nearly 900 disorders caused by a single gene are known to be treatable. Yet the recommended "heel st
Pediatrics March 19,2024
BabySeq 2.0: Bringing equity to genomic sequencing in newborns

BabySeq 2.0: Bringing equity to genomic sequencing in newborns

by Nancy Fliesler,Children's Hospital BostonCredit: Unsplash/CC0 Public DomainToday, nearly 900 disorders caused by a single gene are known to be treatable. Yet the recommended "heel st
Pediatrics March 19,2024
AAO: Research highlights vision issues seen in pediatric sickle cell disease

AAO: Research highlights vision issues seen in pediatric sickle cell disease

by Elana GotkineFor pediatric patients with sickle cell disease (SCD), ophthalmologic complications include nonproliferative retinopathy (NPR) and proliferative retinopathy (PR), which occur in 33 and
Pediatrics March 19,2024
AAO: Research highlights vision issues seen in pediatric sickle cell disease

AAO: Research highlights vision issues seen in pediatric sickle cell disease

by Elana GotkineFor pediatric patients with sickle cell disease (SCD), ophthalmologic complications include nonproliferative retinopathy (NPR) and proliferative retinopathy (PR), which occur in 33 and
Pediatrics March 19,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com